---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027356"
form_type: "8-K"
ticker: null
cik: "0001614067"
company_name: "Aridis Pharmaceuticals, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:21:17.471025+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aridis Pharmaceuticals CFO Fred Kurland resigns effective Aug 4, 2023 due to retirement

## Summary
- CFO Fred Kurland resigned on August 4, 2023, citing retirement.
- Kurland will serve as senior financial consultant to the Company.
- VP of Finance Tamara Allen continues to lead all financial accounting and reporting.

## SEC filing metadata
- accession: 0001493152-23-027356
- form_type: 8-K
- cik: 0001614067
- company_name: Aridis Pharmaceuticals, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1614067/000149315223027356/0001493152-23-027356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1614067/000149315223027356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027356
- JSON: https://secwatch.observer/filing/0001493152-23-027356.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027356.txt

## Key facts
- Executive change
  Fred Kurland resigned as Chief Financial Officer at Aridis Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On August 4, 2023, Fred Kurland resigned as Chief Financial Officer of Aridis Pharmaceuticals, Inc. (the “Company”) due to his retirement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1614067/000149315223027356/0001493152-23-027356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.